Skip to main content

Table 3 Association of rs9939609 with anthropometric, clinical, inflammation and CVD risk biomarkers in children

From: Influence of FTO variants on obesity, inflammation and cardiovascular disease risk biomarkers in Spanish children: a case–control multicentre study

Biomarkers

TT

AT

AA

β (95% CI)

P

Pa

n

162

267

102

   

Anthropometric factors

 

Height (m)

1.38 ± 0.01

1.39 ± 0.01

1.40 ± 0.02

−0.003 (−0.01, 0.00)

0.148

0.594

Weight (kg)

42.3 ± 1.4

45.6 ± 1.1

50.1 ± 2.2

3.31 (1.52, 5.10)

0.001

0.397

BMI (kg/m2)

21.69 ± 0.48

22.89 ± 0.36

24.51 ± 0.64

1.32 (0.59, 2.05)

0.001

--

BMI z-score

1.48 ± 0.16

1.86 ± 0.13

2.32 ± 0.22

0.45 (0.19, 0.71)

0.001

--

Waist circumference (cm)

70.58 ± 1.39

72.85 ± 0.99

77.46 ± 1.71

3.35 (0.61, 6.10)

0.017

0.487

Clinical and metabolic biomarkers

 

Systolic BP (mm Hg)

104 ± 1

104 ± 1

107 ± 1

1.14 (−0.71, 2.99)

0.227

0.466

Diastolic BP (mm Hg)

63 ± 1

65 ± 1

66 ± 1

1.24 (−0.26, 2.74)

0.106

0.888

Glucose (mg/dl)

85 ± 1

84 ± 0

84 ± 1

−0.47 (−1.34, 0.39)

0.286

0.143

Insulin (mU/l)

8.82 ± 0.64

8.73 ± 0.43

9.78 ± 0.71

0.02 (−0.01, 0.05)

0.253

0.225

HOMA-IR

1.89 ± 0.15

1.85 ± 0.10

2.07 ± 0.16

0.02 (−0.02, 0.05)

0.345

0.181

Triacylglycerols (mg/dl)

67 ± 3

64 ± 2

68 ± 4

0.07 (−3.90, 4.03)

0.974

0.216

ApoAI (mg/dl)

142 ± 2

141 ± 2

135 ± 3

−3.01 (−6.36, 0.34)

0.079

0.457

Cholesterol (mg/dl)

169 ± 3

166 ± 2

170 ± 2

0.002 (−0.01, 0.01)

0.721

0.540

HDL-c (mg/dl)

57 ± 1

57 ± 1

55 ± 1

−0.94 (−2.76, 0.89)

0.316

0.509

Adiponectin (mg/l)

25.89 ± 0.95

25.13 ± 0.74

24.16 ± 1.10

−0.72 (−2.18, 0.73)

0.331

0.934

Resistin (μg/l)

10.33 ± 0.44

10.81 ± 0.35

11.43 ± 0.55

0.55 (−0.15, 1.25)

0.125

0.384

Leptin (μg/l)

13.57 ± 1.23

14.37 ± 0.83

16.29 ± 1.52

1.38 (−0.43, 3.18)

0.135

0.149

Inflammatory biomarkers

 

C-reactive protein (mg/l)

2.08 ± 0.29

2.21 ± 0.23

2.77 ± 0.53

0.37 (−0.14, 0.88)

0.153

0.743

IL-6 (ng/l)

5.61 ± 0.90

6.00 ± 0.69

6.19 ± 1.05

0.42 (−0.96, 1.80)

0.550

0.759

IL-8 (ng/l)

1.86 ± 0.16

1.95 ± 0.15

1.83 ± 0.21

0.03 (−0.25, 0.30)

0.853

0.783

TNF-α (ng/l)

3.53 ± 0.16

3.66 ± 0.13

3.33 ± 0.20

−0.02 (−0.27, 0.23)

0.875

0.308

Cardiovascular disease risk biomarkers

 

MMP-9 (μg/l)

80.39 ± 4.35

83.62 ± 3.70

92.82 ± 6.05

0.03 (0.00, 0.07)

0.049

0.048

MPO (μg/l)

17.56 ± 2.06

17.84 ± 1.61

17.65 ± 1.88

0.29 (−2.80, 3.38)

0.853

0.636

sE-Selectin (μg/l)

26.34 ± 1.14

28.22 ± 1.05

26.64 ± 1.40

0.66 (−1.25, 2.56)

0.500

0.711

sICAM-1 (mg/l)

0.162 ± 0.005

0.168 ± 0.004

0.158 ± 0.006

0.001 (−0.01, 0.01)

0.997

0.645

Active PAI-1 (μg/l)

8.35 ± 0.58

8.61 ± 0.52

10.35 ± 0.97

0.85 (−0.19, 1.89)

0.109

0.946

Total PAI-1 (μg/l)

23.22 ± 1.34

22.21 ± 0.92

26.84 ± 2.09

0.02 (−0.02, 0.06)

0.359

0.994

  1. CI: Confidence interval; BMI: body mass index; BP: blood pressure; HOMA-IR: homeostasis model assessment for insulin resistance; HDL-c: high-density lipoprotein cholesterol; IL: interleukin; TNF-α: tumour necrosis factor alpha; MMP-9: matrix metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion molecule-1, PAI-1: plasminogen activator inhibitor. β Coefficients represent the change in absolute traits values of each additional risk allele. General linear models were used to examine associations, P adjusted by age and sex, Pa adjusted by age, sex, and BMI.